The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
HOME > BUSINESS
BUSINESS
- Ono, Carna Biosciences Conclude Capital Alliance Agreement, Making Ono Carna’s Largest Shareholder
October 9, 2012
- GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
- Data Acquisition Completed for Anti-HIV Treatment, Submission for Regulatory Approval in US, Europe Planned By Year End: Shionogi
October 5, 2012
- Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
- Baxter Files for Approval in Japan for Cell Culture Influenza Vaccine
October 4, 2012
- Takeda Initiates Drug Discovery Collaboration with Advinus of India to Boost Research Productivity
October 4, 2012
- Daiichi Sankyo Discontinues PIII Study of ARQ197 in Patients with NSCLC
October 4, 2012
- Sanofi Takes Over 3 Genzyme Products
October 3, 2012
- Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
October 3, 2012
- Seikagaku Completes New Production Facilities for Gel-One to Meet Increasing Demand in US
October 3, 2012
- Shionogi Acquires Worldwide Rights for Cholesterol Absorption Inhibitor from Kotobuki
October 3, 2012
- “Comprehensive Strengths” Have Been Biggest Result of Alliance with Roche: Chairman Nagayama of Chugai
October 3, 2012
- Takeda Receives Approval for Hyperlipidemia Drug Lotriga
October 2, 2012
- Bayer Yakuhin Obtains Approval for VEGF Inhibitor Eylea, Santen to Distribute Product
October 2, 2012
ページ
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…